secwatch.observer — SEC 8-K summary
======================================

Issuer:     Larimar Therapeutics, Inc. (LRMR)
CIK:        0001374690
Form:       8-K
Filed at:   2023-05-12T23:59:59+00:00
Accession:  0000950170-23-021747
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Larimar Therapeutics stockholders elect three Class III directors at 2023 annual meeting
--------------------------------------------------------------------------------

- Elected Frank Thomas, Carole S. Ben-Maimon, and Joseph Truitt as Class III directors until 2026.
- Advisory say-on-pay vote approved with 35.5M votes for, 337.9K against.
- Ratified PricewaterhouseCoopers as independent auditor for FY2023 (40.8M for).
- Broker non-votes of ~4.9M on director elections and say-on-pay.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374690/000095017023021747/0000950170-23-021747-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374690/000095017023021747/lrmr-20230509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-021747

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer